Hartwig Huland

发表

Deep Learning for Natural Language Processing in Urology: State-of-the-Art Automated Extraction of Detailed Pathologic Prostate Cancer Data From Narratively Written Electronic Health Records.

Ulrich Wolffgang, Sami-Ramzi Leyh-Bannurah, Zhe Tian, 2018, JCO clinical cancer informatics.

Development of Technologic Solutions to Address Complex Local Requirements of an International Prostate Cancer Clinical Quality Registry.

Mark Lucas, Hartwig Huland, Sue M Evans, 2019, JCO clinical cancer informatics.

Prostate cancer detection by laser induced autofluorescence and multicomponent spectroscopy

Martin Herms, Hartwig Huland, Markus Graefen, 2007, International Conference on Lasers, Applications, and Technologies.

International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy.

Pierre I Karakiewicz, Hartwig Huland, Markus Graefen, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The feasibility of prostate cancer detection by triple spectroscopy.

Martin Herms, Hartwig Huland, Markus Graefen, 2009, European urology.

Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors.

Hartwig Huland, Markus Graefen, Michael W Kattan, 2003, The Journal of urology.

Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).

Kurt Miller, Hartwig Huland, Andrea Tubaro, 2015, European urology.

Frozen section for the management of intraoperatively detected palpable tumor lesions during nerve-sparing scheduled radical prostatectomy.

Hartwig Huland, Markus Graefen, Thorsten Schlomm, 2006, European urology.

Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.

Yair Lotan, Serge Benayoun, Pierre I Karakiewicz, 2005, The Journal of urology.

Prostate cancers in the transition zone: Part 2; clinical aspects

Hartwig Huland, Markus Graefen, Andreas Erbersdobler, 2004, BJU international.

A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.

Victor Reuter, Hartwig Huland, Markus Graefen, 2003, The Journal of urology.

Detection of Methylated Apoptosis-Associated Genes in Urine Sediments of Bladder Cancer Patients

Gangning Liang, Hartwig Huland, Peter A. Jones, 2004, Clinical Cancer Research.

Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology.

Michael McCormack, Hartwig Huland, Markus Graefen, 2006 .

MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large‐scale tissue microarrays

Malte Buchholz, Michael Becker, Dennis Trede, 2013, International journal of cancer.

Zonal location of prostate cancer: significance for disease-free survival after radical prostatectomy?

Hartwig Huland, Markus Graefen, Fedor Daghofer, 2003, Urology.

Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

Clement Adebamowo, Ritika Kundra, Steven J. M. Jones, 2018, Cell reports.

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.

Mesut Remzi, Hartwig Huland, Martina Tinzl, 2008, European urology.

Magnetic Resonance Imaging of Prostate Cancer: Diffusion-Weighted Imaging in Comparison With Sextant Biopsy

Ralph Buchert, Hartwig Huland, Markus Graefen, 2011, Journal of computer assisted tomography.

Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables.

Pierre I Karakiewicz, Hartwig Huland, Markus Graefen, 2003, European urology.

Quantitative biopsy pathology for the prediction of pathologically organ‐confined prostate carcinoma

Hartwig Huland, Markus Graefen, Robert W Veltri, 2003, Cancer.

Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer

Hartwig Huland, Markus Graefen, Thorsten Schlomm, 2017, Neoplasia.

Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival.

Hartwig Huland, Kim Pettersson, Angel M Cronin, 2009, Clinical chemistry.

A critical appraisal of logistic regression‐based nomograms, artificial neural networks, classification and regression‐tree models, look‐up tables and risk‐group stratification models for prostate cancer

Hartwig Huland, Markus Graefen, Alberto Briganti, 2007, BJU international.

Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology.

Michael McCormack, Pierre I Karakiewicz, Hartwig Huland, 2006, European urology.

Treatment of Prostate Cancer—The Clinical Use of Radical Prostatectomy

Hartwig Huland, H. Huland, J. Noldus, 2003 .

Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma.

Stefan Conrad, Hartwig Huland, Markus Graefen, 2002, The Journal of urology.

Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.

Pierre I Karakiewicz, Hartwig Huland, Markus Graefen, 2009, The Journal of urology.

Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer.

Pierre I Karakiewicz, Hartwig Huland, Markus Graefen, 2004, The Journal of urology.

Expression and prognostic relevance of annexin A3 in prostate cancer.

Martin Schostak, Helmut Klocker, Hartwig Huland, 2008, European urology.

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.

Hartwig Huland, Ville Vaisanen, Andrew J Vickers, 2007, Clinical chemistry.

Defining a standard set of patient-centered outcomes for men with localized prostate cancer.

Steven J Frank, Thomas Wiegel, Ronald C. Chen, 2014, European urology.

Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.

Hartwig Huland, Markus Graefen, Andreas Erbersdobler, 2003, The Journal of urology.

Changing Trends in Surgical Management of Prostate Cancer: The End of Overtreatment?

Hartwig Huland, Markus Graefen, M. Graefen, 2015, European urology.

Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum

Hartwig Huland, Andrew J Vickers, Kim Pettersson, 2006, International journal of cancer.

Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer

Hartwig Huland, Markus Graefen, Thorsten Schlomm, 2010, Clinical Cancer Research.

Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network.

Pierre I Karakiewicz, Hartwig Huland, Markus Graefen, 2007, European urology.

Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysis.

Holger Sültmann, Annemarie Poustka, Hartwig Huland, 2005, International journal of oncology.

Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy.

François Bénard, Pierre I Karakiewicz, Hartwig Huland, 2007, European journal of cancer.